Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 62.06M |
| Revenue (ttm) | 1.62M |
| Net Income (ttm) | -54.66M |
| Shares Out | 31.83M |
| EPS (ttm) | -2.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,934 |
| Open | 2.00 |
| Previous Close | 2.01 |
| Day's Range | 1.93 - 2.06 |
| 52-Week Range | 1.91 - 8.18 |
| Beta | -0.39 |
| Analysts | Buy |
| Price Target | 17.09 (+776.41%) |
| Earnings Date | May 8, 2023 |
About LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for LYRA stock is "Buy." The 12-month stock price forecast is $17.09, which is an increase of 776.41% from the latest price.
News
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localiz...
Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra's Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients --
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing therapies for the localized treatmen...
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...
Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS); Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture All...
Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study
21-point (37%) mean improvement in SNOT-22 total score at six weeks during the uncontrolled Part 1 stage of the 24-week BEACON trial First patient dosed in the randomized, Part 2 stage of the BEACON t...
LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting
Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no symptoms at week 24 after treatment with LYR-210 (7500μg) compared to control The th...
Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
ENLIGHTEN II is the second of two Phase 3 trials enrolling surgically-naïve CRS patients in the Global ENLIGHTEN clinical program. WATERTOWN, Mass.
Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022
WATERTOWN, Mass. , Sept. 6, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enabl...
Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting
WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained a...
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock...
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of chronic rhinosinusitis (CRS) patients, continued enrollment Industry leader Richard Nieman, ...
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
Industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the Company's late-stage product candidates advance in the clinic WATERTOWN, Mass. , J...
Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022
WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained an...
Lyra Therapeutics to Present at Upcoming Investor Conferences
WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained an...
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc...
Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-202...
Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022
LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to co...
7 Stocks to Watch for Major Insider Trading Clues
These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared f...
Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
WATERTOWN, Mass. , April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained,...
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit of LYR-210 to Chroni...
Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
Private placement priced at-the-market under Nasdaq rules Proceeds to support Lyra's ongoing clinical development of LYR-210 and LYR-220 Proceeds, combined with existing cash and expected milestone pa...
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday
We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! The post Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Sto...
Lyra Therapeutics Stock Surges On Equity Raise Of $100M
Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to...